IgGenix Inc, a US-based preclinical antibody discovery and development company, announced on Monday that it has presented data on its lead candidate, IGNX001, an IgG4 monoclonal antibody-based therapeutic for peanut allergy, at the 2024 Annual Conference of the Australasian Society of Clinical Immunology and Allergy (ASCIA) in Adelaide, Australia.

Michael O'Sullivan, MBBS, FRACP, FRCPA, lead investigator, presented information on the company's Phase 1 human clinical trial in peanut allergy. The ACCELERATE Peanut study is active and screening and will assess the safety and tolerability of IGNX001, a therapeutic candidate that is intended to provide the potential for rapid protection for peanut allergic patients.

Derek Croote PhD, IgGenix chief technology officer and co-founder, presented preclinical data on IGNX001, demonstrating robust protection against peanut-mediated mast cell activation, and against anaphylaxis in a murine model of peanut allergy.

The Journal of Allergy and Clinical Immunology has published the complete preclinical findings.